Welcome to our dedicated page for IBEX SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IBEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IBEX's regulatory disclosures and financial reporting.
IBEX Limited reported strong results for its third fiscal quarter ended March 31, 2026 and raised full-year guidance. Revenue rose 16.8% to $164.4 million, driven by double-digit growth across HealthTech, Technology, Travel & Logistics, and Retail & E-commerce.
Net income increased to $13.3 million, with diluted EPS up 21.9% to $0.89. Adjusted EBITDA grew to $22.0 million, while free cash flow improved to $6.6 million. The company now expects fiscal 2026 revenue of $638–$642 million and adjusted EBITDA of $82–$84 million, and highlighted a new strategic AI partnership with Sierra.ai.
IBEX Limited Schedule 13G shows American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute for Medical Research report beneficial ownership of 680,774 shares of IBEX common stock (CUSIP G4690M101 representing 5.1% of the class). The filing lists sole voting power of 673,665 shares and sole dispositive power of 680,774. The registrants state ACIM is an investment adviser and ACIM/ACC/Stowers jointly consented to the filing.
IBEX Ltd director Daniella Ballou-Aares reported selling 6,500 Common Shares in open-market transactions and now holds 10,643 shares directly. The sales included 5,843 shares at $24.2175 and 157 shares at $24.2114 on March 13, 2025, plus 500 shares at $35.01 on December 2, 2025.
Jones John William reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director John William Jones received an equity award of 2,250 common shares through restricted stock units. The RSUs carry a right to one common share each at no cash cost. The award vests 25% on July 1, 2026 and 25% annually for three additional years, contingent on his continued service. Following this grant, his direct ownership totals 15,244 common shares.
IBEX Ltd director Zhuang Mingzhe acquired 2,083 common shares through a stock award. The Form 4 shows a grant of restricted stock units (RSUs) at a price of $0.00 per share, increasing his direct holdings to 7,083 common shares.
The RSUs vest over four years. Twenty‑five percent vest on July 1, 2026, with an additional 25% vesting on each of the next three anniversaries, as long as he remains in continuous service on each vesting date.
Ballou-Aares Daniella reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Daniella Ballou-Aares received an equity award of 2,083 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and increase her direct holdings to 17,143 common shares. Twenty-five percent of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, contingent on her continued service.
McGinnis Patrick reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Patrick McGinnis reported an equity award of 2,083 common shares in the form of restricted stock units (RSUs). The RSUs were granted at no cash price and increase his directly owned common shares to 6,863 after the transaction.
The footnote explains that each RSU represents a contingent right to receive one common share. Twenty-five percent of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, assuming he remains in continuous service on each vesting date.
Beck Fiona Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Fiona Elizabeth Beck reported an equity award. She was granted 2,083 restricted stock units (RSUs), each representing a right to receive one common share at no cost. 25% of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, contingent on continued service. After this grant, her reported direct holdings total 13,583 common shares.
Batungbacal Karen reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Karen Batungbacal reported an equity award of 2,083 common-share-based restricted stock units (RSUs). Each RSU represents the right to receive one common share. According to the vesting schedule, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting on each of the next three yearly anniversaries, as long as she remains in continuous service with the company.
Keen Shuja reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Keen Shuja reported an equity award of 5,000 restricted stock units (RSUs). These RSUs give a contingent right to receive one common share for each unit. According to the grant terms, 25% of the RSUs vest on March 2, 2027, with an additional 25% vesting on the same date in each of the following three years, as long as Shuja remains in continuous service on each vesting date. The award was recorded at a price of $0.00 per share, reflecting that this is a compensation grant rather than an open-market purchase.